scholarly journals Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis

Author(s):  
Mayu Yagita ◽  
Takayoshi Morita ◽  
Atsushi Kumanogoh

Abstract Objectives Denosumab is used for osteoporosis, as it inhibits osteoclast maturation and suppresses bone resorption. Although denosumab is expected to inhibit the bone erosion in rheumatoid arthritis (RA), its therapeutic efficacy is not well established. The aim of this study was to estimate the effects of denosumab on RA through a meta-analysis. Methods A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PubMed, Web of Science and Scopus were searched for original studies providing information on bone mineral density (BMD), joint destruction and disease activity in denosumab-treated RA. A random-effects model was used in the meta-analysis. Results Of the 367 studies identified, 18 met the selection criteria. The BMDs of the lumbar spine, total hip and femoral neck at 12 months after denosumab treatment increased by 5.27% (95% confidence interval: 4.37–6.18), 2.82% (2.46–3.18) and 3.07% (2.66–3.48), respectively. In the sensitivity analysis, age and gender tended to influence the effect of denosumab therapy on the variation rate of BMD, but not glucocorticoid use. The changes in the modified total sharp, erosion and joint space narrowing scores at 12 months after denosumab treatment were significantly smaller with denosumab than with placebo, although the disease activity score did not change after denosumab treatment. Conclusion Although denosumab has an inhibitory effect on the bone resorption in RA, its effects may be influenced by age and gender of RA, but not glucocorticoid use.

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bhaskar Thakur ◽  
Pallavi Dubey ◽  
Joseph Benitez ◽  
Joshua P. Torres ◽  
Sireesha Reddy ◽  
...  

AbstractSeveral comorbidities have been shown to be associated with coronavirus disease 2019 (COVID-19) related severity and mortality. However, considerable variation in the prevalence estimates of comorbidities and their effects on COVID-19 morbidity and mortality have been observed in prior studies. This systematic review and meta-analysis aimed to determine geographical, age, and gender related differences in the prevalence of comorbidities and associated severity and mortality rates among COVID-19 patients. We conducted a search using PubMed, Scopus, and EMBASE to include all COVID-19 studies published between January 1st, 2020 to July 24th, 2020 reporting comorbidities with severity or mortality. We included studies reporting the confirmed diagnosis of COVID-19 on human patients that also provided information on comorbidities or disease outcomes. We used DerSimonian and Laird random effects method for calculating estimates. Of 120 studies with 125,446 patients, the most prevalent comorbidity was hypertension (32%), obesity (25%), diabetes (18%), and cardiovascular disease (16%) while chronic kidney or other renal diseases (51%, 44%), cerebrovascular accident (43%, 44%), and cardiovascular disease (44%, 40%) patients had more COVID-19 severity and mortality respectively. Considerable variation in the prevalence of comorbidities and associated disease severity and mortality in different geographic regions was observed. The highest mortality was observed in studies with Latin American and European patients with any medical condition, mostly older adults (≥ 65 years), and predominantly male patients. Although the US studies observed the highest prevalence of comorbidities in COVID-19 patients, the severity of COVID-19 among each comorbid condition was highest in Asian studies whereas the mortality was highest in the European and Latin American countries. Risk stratification and effective control strategies for the COVID-19 should be done according to comorbidities, age, and gender differences specific to geographical location.


2016 ◽  
Vol 69 (2) ◽  
pp. 157-165 ◽  
Author(s):  
Yang Liu ◽  
Glen S. Hazlewood ◽  
Gilaad G. Kaplan ◽  
Bertus Eksteen ◽  
Cheryl Barnabe

2012 ◽  
Vol 136 (3) ◽  
pp. 212-221 ◽  
Author(s):  
M. Luppa ◽  
C. Sikorski ◽  
T. Luck ◽  
L. Ehreke ◽  
A. Konnopka ◽  
...  

2017 ◽  
Vol Volume 11 ◽  
pp. 1343-1356 ◽  
Author(s):  
Lin Li ◽  
Yafei Cui ◽  
Rulan Yin ◽  
Shengnan Chen ◽  
Qian Zhao ◽  
...  

Author(s):  
Leticia Breda e Vasconcelos ◽  
Tais Freire Galvao

This systematic review assesses the effectiveness and safety of reducing the dose of biological drugs in patients with rheumatoid arthritis at low disease activity, compared to standard dose treatment. Clinical outcomes data were collected and summarized in meta-analysis of standardized mean difference or relative risk. Most outcomes were non-significant.


2018 ◽  
Vol 34 (3) ◽  
pp. 397-407 ◽  
Author(s):  
Sébastien Grenier ◽  
Marie‐Christine Payette ◽  
Bruno Gunther ◽  
Sorayya Askari ◽  
Frédérique F. Desjardins ◽  
...  

IUBMB Life ◽  
2020 ◽  
Vol 72 (12) ◽  
pp. 2563-2571
Author(s):  
Alireza Hejrati ◽  
Mahdi Taghadosi ◽  
Reza Alizadeh‐Navaei ◽  
Shahnaz Hosseinzadeh ◽  
Davood Bashash ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document